丰原药业(000153) - 2019 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2019 was CNY 750,394,431.79, representing a 5.26% increase compared to CNY 712,890,808.20 in the same period last year[8] - Net profit attributable to shareholders was CNY 16,547,254.41, a significant increase of 44.63% from CNY 11,441,363.39 year-on-year[8] - The basic earnings per share increased by 46.81% to CNY 0.0530 from CNY 0.0361 in the same period last year[8] - Total operating revenue for Q1 2019 was CNY 750,394,431.79, an increase of 5.7% compared to CNY 712,890,808.20 in Q1 2018[31] - Net profit for Q1 2019 reached CNY 16,492,551.37, representing a 44.5% increase from CNY 11,441,363.39 in Q1 2018[32] Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 8,207,468.30, which is a decrease of 50.45% compared to CNY 16,564,706.33 in the same period last year[8] - Net cash flow from investing activities dropped significantly by 10154.01% to -RMB 91,287,988.91, reflecting higher cash outflows for investments compared to the previous year[15] - Net cash flow from financing activities decreased by 144.06% to -RMB 26,758,503.18, as cash used for debt repayment exceeded cash received from borrowings[15] - The company incurred research and development expenses of CNY 3,765,315.44, a decrease of 26.5% from CNY 5,121,842.87 in the previous period[33] - The company’s investment activities resulted in a net cash outflow of CNY 91,287,988.91, compared to a net outflow of CNY 890,266.30 in the previous period[37] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,094,692,166.74, reflecting a 2.88% increase from CNY 3,007,997,786.47 at the end of the previous year[8] - The company's current assets totaled CNY 1,762,492,600.55, compared to CNY 1,588,155,611.28 at the end of 2018, reflecting a growth of approximately 10.95%[24][26] - Total liabilities reached CNY 1,789,443,561.94, up from CNY 1,716,211,018.64, marking an increase of approximately 4.26%[26] - The company's equity attributable to shareholders was CNY 1,302,192,243.48, a slight increase from CNY 1,288,675,703.47, reflecting a growth of about 1.06%[26] - The total liabilities as of March 31, 2019, were CNY 1,506,473,827.96, compared to CNY 1,485,847,041.51 at the end of 2018, showing a rise of 1.4%[28] Operational Performance - The total operating costs for Q1 2019 were CNY 728,519,239.96, up from CNY 693,001,331.49 in Q1 2018, reflecting a year-over-year increase of 5.1%[31] - Sales expenses rose by 30.77% to RMB 199,646,563.42, driven by increased market expansion costs corresponding to sales revenue growth[15] - Research and development expenses for Q1 2019 were CNY 9,210,849.95, down from CNY 11,286,274.61 in Q1 2018, a decrease of 18.4%[31] - The company’s sales expenses increased to CNY 78,496,454.14, up 37.0% from CNY 57,280,203.84 in the previous period[33] Financial Position and Changes - The company has decided to invest CNY 20 million to establish the Anhui High-tech Investment New Materials Industry Fund Partnership, which was approved by the board on March 7, 2019[14] - The company has no derivative investments during the reporting period[18] - The company did not report any non-recurring gains or losses that would be classified as regular gains or losses[9] - The company has not undergone an audit for the Q1 2019 report, which may affect the perception of financial reliability[47] - The company is adapting to new financial standards, which may impact future financial reporting and performance metrics[41]